IND Application Submitted to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S....
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials